1 January 2025 in Therapeutic Advances in Medical Oncology
Background: The combination patterns of pathological intermediate-risk factors and the choice of adjuvant therapy for early-stage cervical cancer (CC) remain controversial. Objectives: To develop and validate nomogram-based prediction models incorporating pathological intermediate-risk factors to predict survival outcomes and optimize adjuvant therapy strategies in early-stage CC patients. Design: A multicenter retrospective study. Methods: A total of 1104 patients with stage IB-IIA CC who underwent primary surgical treatment and had no pathological high-risk factors were retrospectively enrolled from three tertiary medical centers in China between January 2005 and December 2017. Patients were randomly assigned to development and validation cohorts (approximately 3:1 ratio). Prognostic models for disease-free survival (DFS) and overall survival (OS) were developed by Cox proportional hazards regression and visualized using nomograms. Results: In this study, four prognostic models were developed incorporating different combinations of five key variables: lymphovascular space involvement (LVSI), stromal invasion (SI), tumor size (TS), histological type, and adjuvant therapy. Among these, Model 4 (LVSI + SI + TS + histological type + adjuvant therapy) demonstrated the highest discriminatory performance, with C-indices of 0.79 for both DFS and OS in the development cohort, and 0.84 for DFS and 0.77 for OS in the validation cohort. Model 4 also effectively stratified patients into prognostic risk groups in both cohorts, with high-risk patients exhibiting significantly worse DFS (development cohort: p < 0.0001; validation cohort: p = 0.0011) and OS (development cohort: p < 0.0001; validation cohort: p = 0.0036) compared to low-risk patients. Conclusion: The nomogram models developed in this study may provide individualized prognostic predictions for early-stage CC patients, potentially facilitating personalized decision-making regarding adjuvant therapy, though further validation in diverse patient cohorts and prospective studies is needed.
1 January 2025 in Therapeutic Advances in Reproductive Health
Background: The placenta accreta spectrum (PAS) represents a significant risk factor for severe postpartum hemorrhage. Recent studies have demonstrated the safety of neuraxial anesthesia (NA) in cesarean delivery (CD) for patients with PAS. Objectives: To evaluate the risk of severe peripartum hemorrhage in patients with PAS who underwent CD under NA. Design: A multicenter retrospective cohort study. Methods: This study analyzed 214 patients diagnosed with PAS. Logistic regression was used to identify factors increasing the risk of severe peripartum hemorrhage. A total of six machine learning (ML) algorithms were employed for model validation. Results: The predictive model includes the following risk factors: age at delivery >33 years ( p = 0.004), history of CD >1 ( p = 0.020), preoperative HGB ⩽ 100 g/L ( p = 0.013), placenta previa classification ( p = 0.001), vascular lacunae within the placenta ( p = 0.015), and labor duration ( p = 0.026). The validation of ML algorithms revealed that the model achieved an accuracy ranging from 0.68 to 0.71, with an area under the receiver operating characteristic curve between 0.75 and 0.79. A nomogram list and web-based calculator were constructed for clinical implementation, and a risk stratification system was established based on model scores. Conclusion: A prenatal risk assessment model was developed to estimate the likelihood of severe peripartum hemorrhage in PAS patients undergoing CD under NA. This model may provide preliminary support for clinicians in tailoring anesthetic management strategies for potentially high-risk cases, but further studies are needed to confirm its clinical utility.
3 January 2026 in International Journal of Gynecological Cancer
Squamous cell carcinoma and adenocarcinoma in early-stage cervical cancer differ in biology and prognosis, yet current guidelines recommend uniform management. This study aimed to develop and internally validate histology-specific prognostic models for squamous cell carcinoma and adenocarcinoma to predict disease-free survival and overall survival, thereby supporting individualized adjuvant therapy for intermediate-risk cervical cancer. A multi-center retrospective analysis was conducted on patients with early-stage cervical cancer who underwent radical surgery without pathologic high-risk features. Patients were stratified into squamous cell carcinoma and adenocarcinoma cohorts. Histology-specific nomograms for disease-free survival and overall survival were developed using Cox regression and internally validated via 5-fold cross-validation. Model discrimination was assessed using the concordance index (C-index), and prognostic stratification using Kaplan-Meier analysis. A total of 1053 patients with stage IB to IIA cervical cancer (911 squamous cell carcinoma, 142 adenocarcinoma) treated at 3 tertiary hospitals from 2005 to 2017 were included. Nomograms incorporating lymphovascular space involvement, stromal invasion, tumor size, and adjuvant therapy showed superior accuracy over Sedlis models (C-indices: 0.81/0.80 for disease-free survival/overall survival in squamous cell carcinoma; 0.91/0.96 for disease-free survival/overall survival in adenocarcinoma). Risk scores stratified patients into distinct prognostic sub-groups. In squamous cell carcinoma, high-risk patients had higher recurrence and mortality rates than low-risk patients (5-year recurrence rate: 11.7% vs 1.6%; mortality rate: 7.7% vs 0.6%). In adenocarcinoma, high-risk patients showed worse outcomes (5-year recurrence rate: 13.3% vs 0.0%; mortality rate: 6.1% vs 0.0%). Kaplan-Meier analysis confirmed significant survival differences across risk groups in both sub-types (all p < .05). Histology-specific nomograms incorporating intermediate-risk factors and adjuvant therapy effectively stratified prognostic sub-groups in early-stage cervical cancer, and may help inform risk-adapted post-operative management. Prospective external validation is needed for broader application.
1 May 2026 in International Journal of Women's Health
Purpose: To evaluate whether antepartum anemia is associated with adverse maternal and perinatal outcomes in women with placenta accreta spectrum (PAS). Patients and Methods: This multicenter retrospective study included 984 women with PAS from three Chinese tertiary hospitals between September 2016 and July 2025. Eligible participants had singleton pregnancies and delivered at ≥ 28 weeks. PAS was confirmed by failure of spontaneous placental separation during delivery or by pathology. Anemia was defined as hemoglobin < 110 g/L. To minimize baseline imbalance, propensity score matching was performed using a 1:1 nearest neighbor matching algorithm with a caliper width of 0.2. Group comparisons used the Chi-square, Fisher’s exact, or Mann–Whitney U test. Univariable and multivariable logistic regression identified independent risk factors for adverse outcomes. Results: Among 984 participants, the incidence of anemia was 32.1%. Anemia group had higher rates of severe PAS subtypes, placenta previa, and vaginal bleeding. The matched analysis included 277 women per group, and the main residual difference was transfusion requirement (median 4 vs 2 units, P < 0.001) and composite adverse maternal outcome (P = 0.006). Multivariable analysis identified anemia as an independent risk factor for adverse maternal outcomes (OR 1.84, 95% CI 1.22– 2.78, P = 0.004). Other independent risk factors included placenta increta/percreta (OR 25.56) and ultrasound signs. Anemia was not associated with adverse perinatal outcomes. Protective factors for perinatal outcomes included longer gestation (OR 0.65) and cesarean delivery (OR 0.01), whereas emergency delivery increased risk (OR 3.75). Conclusion: In women with PAS, antepartum anemia is associated with increased adverse maternal risk, especially transfusion requirements. This supports attention to anemia screening and optimization in PAS care pathways, which may reduce blood resource burden in resource-limited regions. When antepartum anemia cannot be adequately corrected before delivery, sufficient blood preparation is essential.
1 April 2026 in International Journal of Women's Health
High-risk pregnancies (those complicated by antiphospholipid syndrome, rheumatic disease, or adverse obstetric histories) increase the risk of thromboembolic events, for which low-molecular-weight heparin (LMWH) is commonly used. However, LMWH can cause bleeding complications, leading to consideration of alternative anticoagulants. Fondaparinux (FPX), a selective factor Xa inhibitor, has been suggested as an alternative, but its safety and efficacy in pregnancy remain unclear. This study aimed to compare maternal and neonatal outcomes between high-risk pregnant women switched from LMWH to FPX due to bleeding complications and those who continued LMWH. A retrospective cohort study was conducted at a tertiary hospital from January 2018 to June 2024. Pregnant women on LMWH who developed LMWH-related bleeding were switched to FPX and resumed LMWH once bleeding resolved. The comparison group consisted of women who continued LMWH without complications. After propensity score matching (PSM), maternal and neonatal outcomes were compared between the two groups using chi-square tests for categorical variables and rank-sum tests for continuous variables. A total of 159 high‑risk pregnant women were included before propensity score matching (124 in the LMWH group and 35 in the FPX group). After 2:1 matching, 62 patients (40 receiving LMWH and 22 receiving FPX) were analyzed with well‑balanced baseline characteristics between groups. In the matched cohort, rates of miscarriage, gestational age at delivery, live birth, Apgar scores, and neonatal intensive care unit admission were comparable between the two groups (all p > 0.05). Postpartum blood loss within 48 hours was significantly lower in the FPX group (p = 0.016), whereas neonatal birth weight was modestly lower (p = 0.019). Overall, FPX demonstrated a safety profile comparable to LMWH without an increase in adverse maternal or neonatal outcomes. The results are suggestive that FPX may be a safe and effective alternative for pregnant women intolerant to LMWH, associated with reduced postpartum hemorrhage and no increase in adverse outcomes. Further validation through multicenter and prospective studies is needed.
26 June 2026 in International Journal of Gynecological Cancer